Challenges and Opportunities with Checkpoint Inhibition for First-Line Management of Advanced NSCLC

Activity Overview

Immunotherapy has radically transformed the landscape of frontline treatment for advanced non-small cell lung cancer (NSCLC) without actionable mutations. Join us for this live event to hear our expert panel offer privileged insights into evidence-based guidelines for biomarker testing, the latest data pertaining to therapeutic options for NSCLC with high PD-L1 expression, and strategies to address immune-related adverse events. A patient with history of advanced NSCLC will be on the panel to augment these insights with “teaching moments” from his treatment journey.

1.00 CE Credit(s)
Expires: September 14, 2021

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Employ evidence-based biomarker testing for patients with NSCLC
  • Select first-line checkpoint inhibitor therapy for patients with NSCLC based on scientific evidence and therapeutic indications
  • Apply evidence-based strategies for the management of immunotherapy-related adverse events in patients with NSCLC

Activity Faculty

OLYMPUS DIGITAL CAMERA

Solange Peters, MD, PhD (Chair)

Chair and Professor, Medical Oncology
University Hospital of Lausanne
Lausanne, Switzerland

Kerr, Keith - Headshot

Prof. Keith M. Kerr, FRCPath

Honorary Chair, Department of Pathology
Aberdeen University School of Medicine
Aberdeen Royal Infirmary
Foresterhill
Aberdeen, Scotland, United Kingdom 

Ramalingam - Headshot

Suresh S. Ramalingam, MD, FACP, FASCO

Professor, Hematology and Medical Oncology
Roberto C. Goizueta Chair, Cancer Research
Director, Division of Medical Oncology
Assistant Dean, Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States